Abstract | BACKGROUND: METHODS: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay. RESULTS: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P=0.041) and reduced overall survival (P=0.002). CONCLUSION:
Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.
|
Authors | U Wallin, B Glimelius, K Jirström, S Darmanis, R Y Nong, F Pontén, C Johansson, L Påhlman, H Birgisson |
Journal | British journal of cancer
(Br J Cancer)
Vol. 104
Issue 10
Pg. 1619-27
(May 10 2011)
ISSN: 1532-1827 [Electronic] England |
PMID | 21468045
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Growth Differentiation Factor 15
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(biosynthesis)
- Cohort Studies
- Colorectal Neoplasms
(metabolism, pathology)
- Female
- Growth Differentiation Factor 15
(biosynthesis)
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(metabolism, pathology)
- Prognosis
- Prospective Studies
- Survival Analysis
|